Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024440 · ClinicalTrials.gov registry record · Phase 3
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00024440: Completed Phase 3 study, sponsored by Genta Incorporated.
NCT00024440 is a Phase 3 study that has completed, run by Genta Incorporated. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024440, a Phase 3 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to the drugs. It is not yet known if fludarabine and cyclophosphamide are more effective with or without oblimersen. PURPOSE: Randomized phase III trial to compare the effectiveness of fludarabine and cyclophosphamide with or without oblimersen in treating patients who have relapsed or refractory chronic lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL filgrastim
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00024440 record still lists
NCT00024440 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00024440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00024440 about?
NCT00024440 is a clinical study titled "Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to the drugs. It is not yet known if fludarabine and cyclophosphamide are...
What is the current status of trial NCT00024440?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-07. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00024440?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), filgrastim (BIOLOGICAL), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00024440?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia